AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Brief description of study

The primary aim of this study is to assess in a randomized fashion whether or not the incorporation of two cycles of inotuzumab ozogamicin (InO) into a modified Berlin-Frankfurt-Munster (mBFM) chemotherapy backbone will improve disease-free survival.


Clinical Study Identifier: s19-01819
ClinicalTrials.gov Identifier: NCT03959085


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.